ArticleFrontiers in pharmacology2023

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.

Xuesong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.